I've seen this before,The additional data secondary endpoints were omitted from the investor presentation but a peek into the data shows that
with 125 patients
Arikace, had 35% more adverse efeects overall
7.4% of patients(twice as many as TOBI) had severe events
This issue will come up again
Which pharma is paying you and the rest of your boiler room gang? Makes no difference. They will have to get on a long line with lots of cash to acquire Insmed some day, if ever. Suggestion: talk to an attorney to find out if what you are doing is legal. Insmed has attorneys who can quickly come after your gang. Have a nice day.
Wow - another delusional poster under the impression his opinion is of value when we already have the opinion of the Canaccord analyst -
"We see Arikace as eminently approvable with good safety. While there are optical imbalances in Arikace's severe adverse events, INSM indicated there is no kidney or ototox signal, our main concern."
Perhaps you should take a closer look at the data already released - and then take a look at the problematical efficacy and safety data from the study of Tobi Inhalation Powder vs nebulised Tobi, which the FDA felt was outweighed by the prospect of better compliance because twice-daily TIP is less time-consuming that twice-daily nebulised Tobi.
Number of subjects with treatment-emergent adverse events by seriousness -